Logo image of PHGE

BIOMX INC (PHGE) Stock Fundamental Analysis

USA - NYSEARCA:PHGE - US09090D3017 - Common Stock

0.35 USD
-0.03 (-6.99%)
Last: 11/13/2025, 8:04:00 PM
0.3451 USD
0 (-1.4%)
After Hours: 11/13/2025, 8:04:00 PM
Fundamental Rating

2

Overall PHGE gets a fundamental rating of 2 out of 10. We evaluated PHGE against 531 industry peers in the Biotechnology industry. PHGE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PHGE does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

PHGE had negative earnings in the past year.
PHGE had a negative operating cash flow in the past year.
In the past 5 years PHGE always reported negative net income.
PHGE had a negative operating cash flow in each of the past 5 years.
PHGE Yearly Net Income VS EBIT VS OCF VS FCFPHGE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M

1.2 Ratios

The Return On Assets of PHGE (-48.80%) is comparable to the rest of the industry.
PHGE has a Return On Equity (-96.91%) which is in line with its industry peers.
Industry RankSector Rank
ROA -48.8%
ROE -96.91%
ROIC N/A
ROA(3y)-69.25%
ROA(5y)-59.4%
ROE(3y)-352.46%
ROE(5y)-237.19%
ROIC(3y)N/A
ROIC(5y)N/A
PHGE Yearly ROA, ROE, ROICPHGE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PHGE so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PHGE Yearly Profit, Operating, Gross MarginsPHGE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, PHGE has less shares outstanding
Compared to 5 years ago, PHGE has more shares outstanding
PHGE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PHGE Yearly Shares OutstandingPHGE Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
PHGE Yearly Total Debt VS Total AssetsPHGE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

PHGE has an Altman-Z score of -9.55. This is a bad value and indicates that PHGE is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -9.55, PHGE is not doing good in the industry: 71.19% of the companies in the same industry are doing better.
PHGE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -9.55
ROIC/WACCN/A
WACCN/A
PHGE Yearly LT Debt VS Equity VS FCFPHGE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

PHGE has a Current Ratio of 2.66. This indicates that PHGE is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.66, PHGE is doing worse than 67.80% of the companies in the same industry.
PHGE has a Quick Ratio of 2.66. This indicates that PHGE is financially healthy and has no problem in meeting its short term obligations.
PHGE's Quick ratio of 2.66 is on the low side compared to the rest of the industry. PHGE is outperformed by 66.10% of its industry peers.
Industry RankSector Rank
Current Ratio 2.66
Quick Ratio 2.66
PHGE Yearly Current Assets VS Current LiabilitesPHGE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

1

3. Growth

3.1 Past

PHGE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 43.62%, which is quite impressive.
EPS 1Y (TTM)43.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 12.10% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y50.83%
EPS Next 2Y31.18%
EPS Next 3Y20.99%
EPS Next 5Y12.1%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PHGE Yearly Revenue VS EstimatesPHGE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2028 2029 2030 2031 2032 100M 200M 300M
PHGE Yearly EPS VS EstimatesPHGE Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PHGE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PHGE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PHGE Price Earnings VS Forward Price EarningsPHGE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PHGE Per share dataPHGE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

PHGE's earnings are expected to grow with 20.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.18%
EPS Next 3Y20.99%

0

5. Dividend

5.1 Amount

PHGE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

BIOMX INC

NYSEARCA:PHGE (11/13/2025, 8:04:00 PM)

After market: 0.3451 0 (-1.4%)

0.35

-0.03 (-6.99%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)03-23 2026-03-23/amc
Inst Owners40.03%
Inst Owner Change-0.73%
Ins Owners1.46%
Ins Owner Change0%
Market Cap9.29M
Revenue(TTM)N/A
Net Income(TTM)-18.57M
Analysts82.5
Price Target15.81 (4417.14%)
Short Float %0.81%
Short Ratio0.43
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)20.96%
Min EPS beat(2)-0.76%
Max EPS beat(2)42.68%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-16.22%
EPS NQ rev (1m)0%
EPS NQ rev (3m)21.95%
EPS NY rev (1m)0%
EPS NY rev (3m)5.23%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.48
P/tB 1.31
EV/EBITDA N/A
EPS(TTM)-1.56
EYN/A
EPS(NY)-1.48
Fwd EYN/A
FCF(TTM)-1.1
FCFYN/A
OCF(TTM)-1.1
OCFYN/A
SpS0
BVpS0.72
TBVpS0.27
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -48.8%
ROE -96.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-69.25%
ROA(5y)-59.4%
ROE(3y)-352.46%
ROE(5y)-237.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.66
Quick Ratio 2.66
Altman-Z -9.55
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)3.92%
Cap/Depr(5y)40.26%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y50.83%
EPS Next 2Y31.18%
EPS Next 3Y20.99%
EPS Next 5Y12.1%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-18.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year0.68%
EBIT Next 3Y-11.29%
EBIT Next 5Y-5.98%
FCF growth 1Y-34.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-34.22%
OCF growth 3YN/A
OCF growth 5YN/A

BIOMX INC / PHGE FAQ

What is the fundamental rating for PHGE stock?

ChartMill assigns a fundamental rating of 2 / 10 to PHGE.


What is the valuation status for PHGE stock?

ChartMill assigns a valuation rating of 1 / 10 to BIOMX INC (PHGE). This can be considered as Overvalued.


Can you provide the profitability details for BIOMX INC?

BIOMX INC (PHGE) has a profitability rating of 1 / 10.


Can you provide the financial health for PHGE stock?

The financial health rating of BIOMX INC (PHGE) is 6 / 10.


What is the expected EPS growth for BIOMX INC (PHGE) stock?

The Earnings per Share (EPS) of BIOMX INC (PHGE) is expected to grow by 50.83% in the next year.